BriaCell Bria-IMT ASCO 2026 Biomarker Detail: 65% of Heavily Pretreated Breast Cancer Patients Showed CAML Stability/Drop Correlating With Better Progression-Free Survival
BriaCell's ASCO 2026 poster presentations added a biomarker finding beyond the headline 16.6-month median overall survival for Bria-IMT. In an ongoing analysis of heavily pretreated metastatic breast cancer patients, 65% showed stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs) — circulating cells in the blood that reflect tumor activity — and that change significantly correlated with better progression-free survival. The CAML biomarker offers a potential early blood-based readout of Bria-IMT response, which matters for an immunotherapy where conventional imaging can lag the immune response. BriaCell's six ASCO 2026 data items (three posters, three publication-only abstracts) cover the pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor plus further Phase 2 analyses. Bria-IMT is a whole-cell allogeneic peptide-and-cell immunotherapy in heavily pretreated metastatic breast cancer that has failed ADC, checkpoint, and CDK4/6 inhibitor therapy. The biomarker work supports patient selection and response monitoring as the program advances toward accelerated-approval discussions.